Product Description
BEBT-109 is being developed by Guangzhou Bibet Pharmaceutical Technology for the treatment of EGFR-mutant non-small cell lung cancer. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/33321427/)
Mechanisms of Action: EGFR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: BeBetter Med Inc
Company Location: Eastern America
Company Founding Year: 2016
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 4
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Non-Small-Cell Lung Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06514027 |
GBMT-109-P04 | P2 |
Not yet recruiting |
Non-Small-Cell Lung Cancer |
2027-06-01 |
2024-07-24 |
Primary Endpoints|Treatments |
|
CTR20192575 |
CTR20192575 | P1 |
Completed |
Non-Small-Cell Lung Cancer |
2024-03-13 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
NCT06706713 |
GBMT-109-P02 | P2 |
Recruiting |
Non-Small-Cell Lung Cancer |
2025-12-31 |
2024-11-27 |
Primary Endpoints|Treatments |
|
CTR20213409 |
CTR20213409 | P2 |
Recruiting |
Non-Small-Cell Lung Cancer |
None |
2025-04-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|